HCP
TAK icon

Hexagon Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Hexagon Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,027
Closed -$204K – 277
2026
Q1 		$204K Buy
11,027
+697
+7% +$12.2K 0.03% 244
2025
Q4 		$161K Buy
+10,330
New +$148K 0.03% 74
2025
Q3 		– Sell
-11,360
Closed -$176K – 78
2025
Q2 		$176K Buy
11,360
+2,662
+31% +$39.3K 0.04% 69
2025
Q1 		$129K Buy
8,698
+3,008
+53% +$42.1K 0.02% 274
2024
Q4 		$75.3K Buy
5,690
+1,271
+29% +$17.5K 0.01% 383
2024
Q3 		$62.8K Buy
4,419
+1,129
+34% +$16K 0.01% 405
2024
Q2 		$42.6K Sell
3,290
-1,315
-29% -$17.4K 0.01% 468
2024
Q1 		$64K Sell
4,605
-15
-0.3% -$218 0.01% 380
2023
Q4 		$65.9K Sell
4,620
-928
-17% -$13.2K 0.02% 352
2023
Q3 		$85.8K Buy
5,548
+2,199
+66% +$34K 0.02% 283
2023
Q2 		$52.6K Sell
3,349
-907
-21% -$14.9K 0.01% 349
2023
Q1 		$70.1K Buy
4,256
+377
+10% +$6K 0.02% 298
2022
Q4 		$60.5K Sell
3,879
-837
-18% -$11.7K 0.02% 319
2022
Q3 		$61K Buy
4,716
+3,569
+311% +$49.6K 0.02% 332
2022
Q2 		$16K Buy
+1,147
New +$16.4K ﹤0.01% 585

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Hexagon Capital Partners's TAK Position: Q2 2026 in Review

Hexagon Capital Partners sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 11,027 shares — an estimated $204K sold.

Hexagon Capital Partners first reported a position in TAK in Q2 2022 and held it in 15 quarters. The position peaked at $204K in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Hexagon Capital Partners reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Hexagon Capital Partners sold 11,027 Takeda Pharmaceutical shares in Q2 2026, an estimated $204K.
  • Hexagon Capital Partners first reported a position in Takeda Pharmaceutical in Q2 2022 and held it in 15 quarters.
  • Hexagon Capital Partners's Takeda Pharmaceutical position peaked at $204K in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Hexagon Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.